Keyword: Agios Pharmaceuticals

Agios

20. Tibsovo

Tibsovo won't be a blockbuster with peak sales hovering around the $300 million mark, but it’s still on the hook to treat around 700 to 1,100 AML patients with the IDH1 mutation in the U.S.